A novel stem cell therapy for hepatitis B virus-related acute-on-chronic liver failure
The aim of this study was to propose a stem cell therapy for hepatitis B virus (HBV)-related acute-on-chronic liver failure (ACLF) based on plasma exchange (PE) for peripheral blood stem cell (PBSC) collection and examine its safety and efficacy. Sixty patients (n=20 in each group) were randomized to PE (PE alone), granulocyte colony-stimulating factor (G-CSF) (PE after G-CSF treatment), and PBSC transplantation (PBSCT) (G-CSF, PE, PBSC collection and hepatic artery injection) groups. Patients were followed-up for 24 weeks. Liver function and adverse events were recorded. Survival analysis was performed. PBSCT improved blood ammonia levels at 1 week (P<0.05). The level of total bilirubin, international normalized ratio, and creatinine showed significant differences in the 4th week of treatment (P<0.05). The survival rates of the PE, G-CSF, and PBSCT groups were 50, 65, and 85% at 90 days (P=0.034). There was a significant difference in 90-day survival between the PE and PBSCT groups (P=0.021). The preliminary results suggested that PBSCT was safe, with a possibility of improved 90-day survival in patients with HBV-ACLF.
Main Authors: | , , , , , , , , , , , |
---|---|
Format: | Digital revista |
Language: | English |
Published: |
Associação Brasileira de Divulgação Científica
2020
|
Online Access: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2020001100613 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
oai:scielo:S0100-879X2020001100613 |
---|---|
record_format |
ojs |
spelling |
oai:scielo:S0100-879X20200011006132020-10-05A novel stem cell therapy for hepatitis B virus-related acute-on-chronic liver failureZhu,BingYou,ShaoliRong,YihuiYu,QiangLv,SaSong,FangjiaoLiu,HonglingWang,HuamingZhao,JunLi,DongzeLiu,WanshuXin,Shaojie Stem cell transplantation Hepatic artery transfusion Acute-on-chronic liver failure Hepatitis B virus Randomized controlled trial The aim of this study was to propose a stem cell therapy for hepatitis B virus (HBV)-related acute-on-chronic liver failure (ACLF) based on plasma exchange (PE) for peripheral blood stem cell (PBSC) collection and examine its safety and efficacy. Sixty patients (n=20 in each group) were randomized to PE (PE alone), granulocyte colony-stimulating factor (G-CSF) (PE after G-CSF treatment), and PBSC transplantation (PBSCT) (G-CSF, PE, PBSC collection and hepatic artery injection) groups. Patients were followed-up for 24 weeks. Liver function and adverse events were recorded. Survival analysis was performed. PBSCT improved blood ammonia levels at 1 week (P<0.05). The level of total bilirubin, international normalized ratio, and creatinine showed significant differences in the 4th week of treatment (P<0.05). The survival rates of the PE, G-CSF, and PBSCT groups were 50, 65, and 85% at 90 days (P=0.034). There was a significant difference in 90-day survival between the PE and PBSCT groups (P=0.021). The preliminary results suggested that PBSCT was safe, with a possibility of improved 90-day survival in patients with HBV-ACLF.info:eu-repo/semantics/openAccessAssociação Brasileira de Divulgação CientíficaBrazilian Journal of Medical and Biological Research v.53 n.11 20202020-01-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2020001100613en10.1590/1414-431x20209728 |
institution |
SCIELO |
collection |
OJS |
country |
Brasil |
countrycode |
BR |
component |
Revista |
access |
En linea |
databasecode |
rev-scielo-br |
tag |
revista |
region |
America del Sur |
libraryname |
SciELO |
language |
English |
format |
Digital |
author |
Zhu,Bing You,Shaoli Rong,Yihui Yu,Qiang Lv,Sa Song,Fangjiao Liu,Hongling Wang,Huaming Zhao,Jun Li,Dongze Liu,Wanshu Xin,Shaojie |
spellingShingle |
Zhu,Bing You,Shaoli Rong,Yihui Yu,Qiang Lv,Sa Song,Fangjiao Liu,Hongling Wang,Huaming Zhao,Jun Li,Dongze Liu,Wanshu Xin,Shaojie A novel stem cell therapy for hepatitis B virus-related acute-on-chronic liver failure |
author_facet |
Zhu,Bing You,Shaoli Rong,Yihui Yu,Qiang Lv,Sa Song,Fangjiao Liu,Hongling Wang,Huaming Zhao,Jun Li,Dongze Liu,Wanshu Xin,Shaojie |
author_sort |
Zhu,Bing |
title |
A novel stem cell therapy for hepatitis B virus-related acute-on-chronic liver failure |
title_short |
A novel stem cell therapy for hepatitis B virus-related acute-on-chronic liver failure |
title_full |
A novel stem cell therapy for hepatitis B virus-related acute-on-chronic liver failure |
title_fullStr |
A novel stem cell therapy for hepatitis B virus-related acute-on-chronic liver failure |
title_full_unstemmed |
A novel stem cell therapy for hepatitis B virus-related acute-on-chronic liver failure |
title_sort |
novel stem cell therapy for hepatitis b virus-related acute-on-chronic liver failure |
description |
The aim of this study was to propose a stem cell therapy for hepatitis B virus (HBV)-related acute-on-chronic liver failure (ACLF) based on plasma exchange (PE) for peripheral blood stem cell (PBSC) collection and examine its safety and efficacy. Sixty patients (n=20 in each group) were randomized to PE (PE alone), granulocyte colony-stimulating factor (G-CSF) (PE after G-CSF treatment), and PBSC transplantation (PBSCT) (G-CSF, PE, PBSC collection and hepatic artery injection) groups. Patients were followed-up for 24 weeks. Liver function and adverse events were recorded. Survival analysis was performed. PBSCT improved blood ammonia levels at 1 week (P<0.05). The level of total bilirubin, international normalized ratio, and creatinine showed significant differences in the 4th week of treatment (P<0.05). The survival rates of the PE, G-CSF, and PBSCT groups were 50, 65, and 85% at 90 days (P=0.034). There was a significant difference in 90-day survival between the PE and PBSCT groups (P=0.021). The preliminary results suggested that PBSCT was safe, with a possibility of improved 90-day survival in patients with HBV-ACLF. |
publisher |
Associação Brasileira de Divulgação Científica |
publishDate |
2020 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2020001100613 |
work_keys_str_mv |
AT zhubing anovelstemcelltherapyforhepatitisbvirusrelatedacuteonchronicliverfailure AT youshaoli anovelstemcelltherapyforhepatitisbvirusrelatedacuteonchronicliverfailure AT rongyihui anovelstemcelltherapyforhepatitisbvirusrelatedacuteonchronicliverfailure AT yuqiang anovelstemcelltherapyforhepatitisbvirusrelatedacuteonchronicliverfailure AT lvsa anovelstemcelltherapyforhepatitisbvirusrelatedacuteonchronicliverfailure AT songfangjiao anovelstemcelltherapyforhepatitisbvirusrelatedacuteonchronicliverfailure AT liuhongling anovelstemcelltherapyforhepatitisbvirusrelatedacuteonchronicliverfailure AT wanghuaming anovelstemcelltherapyforhepatitisbvirusrelatedacuteonchronicliverfailure AT zhaojun anovelstemcelltherapyforhepatitisbvirusrelatedacuteonchronicliverfailure AT lidongze anovelstemcelltherapyforhepatitisbvirusrelatedacuteonchronicliverfailure AT liuwanshu anovelstemcelltherapyforhepatitisbvirusrelatedacuteonchronicliverfailure AT xinshaojie anovelstemcelltherapyforhepatitisbvirusrelatedacuteonchronicliverfailure AT zhubing novelstemcelltherapyforhepatitisbvirusrelatedacuteonchronicliverfailure AT youshaoli novelstemcelltherapyforhepatitisbvirusrelatedacuteonchronicliverfailure AT rongyihui novelstemcelltherapyforhepatitisbvirusrelatedacuteonchronicliverfailure AT yuqiang novelstemcelltherapyforhepatitisbvirusrelatedacuteonchronicliverfailure AT lvsa novelstemcelltherapyforhepatitisbvirusrelatedacuteonchronicliverfailure AT songfangjiao novelstemcelltherapyforhepatitisbvirusrelatedacuteonchronicliverfailure AT liuhongling novelstemcelltherapyforhepatitisbvirusrelatedacuteonchronicliverfailure AT wanghuaming novelstemcelltherapyforhepatitisbvirusrelatedacuteonchronicliverfailure AT zhaojun novelstemcelltherapyforhepatitisbvirusrelatedacuteonchronicliverfailure AT lidongze novelstemcelltherapyforhepatitisbvirusrelatedacuteonchronicliverfailure AT liuwanshu novelstemcelltherapyforhepatitisbvirusrelatedacuteonchronicliverfailure AT xinshaojie novelstemcelltherapyforhepatitisbvirusrelatedacuteonchronicliverfailure |
_version_ |
1756391617443397632 |